Gapping up
In reaction to earnings/guidance:
- KFY +6.7%, TWST +3.8%, CEL +1.9%
Select travel related names showing strength:
- NCLH +3.3%, CCL +3.1%, HA +3%, RCL +1.9%, DAL +1.8%, UAL +1.8%, SAVE +1.8%, AAL +1.7%, ALK +1.6%, JBLU +1.6%, .
Other news:
- IDEX +32.5% (has increased its stake in California-based Solectrac, Inc. through a follow-on investment of an additional $1.3 million)
- RESI +20.2% (Front Yard Residential amended merger agreement with Pretium and Ares Management -- consideration increased to $16.25/share from $13.50/share)
- APXT +10.3% (AvePoint, the largest Microsoft (MSFT) 365 data management solutions provider, announces $2bn merger with APXT)
- EIGR +9.9% (FDA approves Zokinvy for HGPS or Progeria and processing-deficient Progeroid Laminopathies)
- SDGR +6.5% (Announces a multi-target drug discovery, development, and commercialization collaboration with Bristol Myers Squibb (BMY))
- REGN +4.1% (receives Emergency Use Authorization for REGEN-COV2 antibody cocktail)
- BCLI +3.9% (to present NurOwn Phase 3 clinical trial results)
- NVTA +3.3% (confirms the FDA accepted the submission of a premarket approval application for a companion diagnostic claim for STRATAFIDE on Nov 18)
- RIGL +3.3% (Rigel Pharma and Medison Pharma announced that Health Canada has approved the new drug submission for TAVALISSE for the treatment of thrombocytopenia)
- PEIX +2.9% (files for 8,900,493 share common stock offering by selling shareholder)
- CSIQ +2.7% (signed a power purchase agreement with BTG Pactual and was awarded with two projects in a private auction by Furnas Centrais Elétricas)
- AON +2.4% (authorizes additional $5.0 bln share repurchase program)
- SMMT +2.3% (Dr. Mahkam Zanganeh has been appointed as Chief Operating Officer, effective immediately)
- MRK +2% (will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash)
- VFF +1.6% (receives cannabis research license for on-site sensory evaluation from Health Canada / Pure Sunfarms Brand debuts internationally )
- CGC +1.6% (announces completion of study on the long-term effects of CBD)
- BDX +1.3% (announces streamlined reporting capabilities for COVID-19 Data)
- PFE +1.2% (FDA has scheduled a meeting for December 10 to discuss the request for EUA of a COVID-19 vaccine)